He is not going to be out of a job haha. I respect many of your points, but that is just not going to happen. Bob pretty much is MMR. Without him, this stock and company probably closes up shop within a few months.
As for the OS, dilution, share price, etc. Yes, dilution has taken its toll on the stock. Basically the market cap is the same now, around $15-$16 M, as it was 3 years ago when the stock was at 10 cents. The decline in share price is the cost of doing business for OTC companies that as of yet do not have enough revenue to cover costs. That is one of the main reasons companies go public, to use their shares as cash so to speak. Even the biggest Nasdaq companies do it. How many nasdaq biotech companies do you know of that have diluted and RS the past few years? Hundreds and hundreds. So to say MMR is a pariah because of dilution is just burying your head in the sand. It's par for the course for almost every public company that is not cash solvent.
You are correct that many of the pr's put out the past few years have not lived up to expectations. The $5 M rapid rev pr put out last year being one of them. We shall see total revenues for 2012 within the next few days in the Annual report, but I am guessing they won't be $5 M. That being said, I am very hopeful still that many of the irons in the fire to increase revenue will begin to pay off this year. Some possibly of the 'whopper' variety.
Good luck.
News 
Market Data 
Discover 
